Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04728009
Other study ID # REH-62320
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date May 15, 2020

Study information

Verified date January 2021
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to preliminarily determine safety and efficacy of longan and lingzhi mushroom syrup on immune and inflammatory responses. Apparently healthy Thai adults (N = 8) aged 18-60 years were recruited into a prospective, single-group study. All participants were assigned to consume 5 mL of longan and lingzhi mushroom syrup daily for 12 weeks. Blood concentrations of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), BUN (blood urea nitrogen), creatinine (Cr), immunoglobulins (IgG, IgM, IgA, and IgE), and C-reactive protein (CRP) were measured at baseline (week 0), week 4, week 8, and week 12.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 15, 2020
Est. primary completion date May 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Apparently healthy adults at Mae Fah Luang University and Chulalongkorn University 2. aged 18-60 years 3. HbA1c < 7% Exclusion Criteria: 1. self-reported immunodeficiency diseases, autoimmune diseases, infectious diseases, diabetes, thyroid diseases, cancer, hepatic- and/or renal dysfunction, uncontrollable illnesses and life-threatening diseases 2. being allergic to longan and lingzhi products 3. taking medications, herbs, and diet supplements affecting immune system, inflammatory response, and blood glucose a month before study enrollment 4. pregnant and breastfeeding women

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Longan and lingzhi mushroom syrup
Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.

Locations

Country Name City State
Thailand Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse effects on fasting blood glucose Blood concentrations of fasting blood glucose (in mg/dL) were measured. 12 weeks
Primary Adverse effects on long-term glycemic control Blood concentrations of HbA1C (in %) were measured. 12 weeks
Primary Adverse effects on hepatic function (1) Blood concentrations of aspatate aminotransferase (AST) (in units/L) were measured. 12 weeks
Primary Adverse effects on hepatic function (2) Blood concentrations of alanine aminotransferase (ALT) (in units/L) were measured. 12 weeks
Primary Adverse effects on hepatic function (3) Blood concentrations of alkaline phosphatase (ALP) (in units/L) were measured. 12 weeks
Primary Adverse effects on renal function (1) Blood concentrations of blood urea nitrogen (in mg/dL) were measured. 12 weeks
Primary Adverse effects on renal function (2) Blood concentrations of serum creatinine (in mg/dL) were measured. 12 weeks
Secondary Effect on immune responses (1) Blood concentrations of immunoglobulin (Ig) G (in mg/dL) were measured. 12 weeks
Secondary Effect on immune responses (2) Blood concentrations of Ig M (in mg/dL) were measured. 12 weeks
Secondary Effect on immune responses (3) Blood concentrations of Ig A (in mg/dL) were measured. 12 weeks
Secondary Effect on immune responses (4) Blood concentrations of Ig E (in IU/mL) were measured. 12 weeks
Secondary Effect on inflammatory responses Blood concentrations of C-reactive protein (in mg/L) were measured. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04485481 - Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Phase 1
Completed NCT03473236 - Phase 1A Safety Trial of Inhaled PK10571 (GB002) Phase 1
Not yet recruiting NCT03683953 - The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells Phase 1
Recruiting NCT05546567 - NOPARK Open Label Extension Study N/A
Recruiting NCT05413226 - Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility N/A
Recruiting NCT05112159 - Study of IPG1094 in Healthy Participants Phase 1
Completed NCT04689035 - A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 Phase 1
Completed NCT04335045 - Phase I Study of PH100 (Ecklonia Cava Phlorotannins) Phase 1
Completed NCT05037227 - Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
Recruiting NCT05517291 - DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease N/A
Enrolling by invitation NCT06446778 - Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Completed NCT05585463 - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Completed NCT04188821 - Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander N/A
Completed NCT03667430 - Safety Evaluation of Porous Silica in Men N/A
Completed NCT04499482 - Safety and Tolerability of Soy Fiber N/A
Completed NCT03141905 - Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease N/A
Completed NCT05244161 - A Quasi-experimental Evaluation of the Malezi Program in Tanzania N/A
Recruiting NCT03791372 - Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy Phase 1
Not yet recruiting NCT04774900 - Standardization of Ambulance Equipment